Calcium‐permeable AMPA receptors are involved in the induction and expression of l‐DOPA‐induced dyskinesia in Parkinson’s disease
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
J. Neurochem.(2010)114, 409–511. Overactivity of striatal α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) glutamate receptors is implicated in the pathophysiology of l‐DOPA‐induced dyskinesia (LID) in Parkinson’s disease (PD). In this study, we evaluated the behavioural and molecular effects of acute and chronic blockade of Ca 2+‐permeable AMPA receptors in animal models of PD and LID. The acute effects of the Ca 2+‐permeable AMPA receptor antagonist 1‐trimethylammonio‐5‐(1‐adamantane‐methylammoniopentane) dibromide hydrobromide (IEM 1460) on abnormal involuntary movements (AIMs) in the 6‐hydroxydopamine (6‐OHDA)‐lesioned rat and LID in the MPTP‐lesioned non‐human primate were assessed. Subsequently, the effects of chronic treatment of 6‐OHDA‐lesioned rats with vehicle,l‐DOPA/benserazide (6/15 mg/kg, i.p.) + vehicle or l‐DOPA + IEM 1460 (3 mg/kg, i.p.) on behavioural and molecular correlates of priming for LID were evaluated. In the 6‐OHDA‐lesioned rat and MPTP‐lesioned non‐human primate, acute treatment with IEM 1460 (1–3 mg/kg) dose‐dependently reduced LID without adverse effects on motor performance. Chronic co‐treatment for 21 days with IEM 1460 reduced the induction of AIMs by l‐DOPA in the 6‐OHDA‐lesioned rat without affecting peak rotarod performance, and attenuated AIMs score by 75% following l‐DOPA challenge (p < 0.05). Chronic IEM 1460 treatment reversed l‐DOPA‐induced up‐regulation of pre‐proenkephalin‐A, and normalised pre‐proenkephalin‐B mRNA expression in the lateral striatum, indicating an inhibition of both behavioural and molecular correlates of priming. These data suggest that Ca 2+‐permeable AMPA receptors are critically involved in both the induction and subsequent expression of LID, and represent a potential target for anti‐dyskinetic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Family of AMPA-Selective Glutamate Receptors
Keinänen, K., Wisden, W., Sommer, B., Werner, P., Herb, A., Verdoorn, T. A., Sakmann, B., & Seeburg, P. H. (1990) · Science · doi:10.1126/science.2166337 · Cited by 1,479 · cited 1×
“(2010) 114, 499–511 499 a-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors (GluR) are tetrameric structures composed of combinations of subunits named GluR1–4 (Keinanen et al. 1990).”
BackgroundRegulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity
Lee, H.-K., Barbarosie, M., Kameyama, K., Bear, M. F., & Huganir, R. L. (2000) · Nature · doi:10.1038/35016089 · Cited by 1,116
Burnashev, N., Monyer, H., Seeburg, P. H., & Sakmann, B. (1992) · Neuron · doi:10.1016/0896-6273(92)90120-3 · Cited by 1,087
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., & Calabresi, P. (2003) · Nature Neuroscience · doi:10.1038/nn1040 · Cited by 821 · cited 4×
“Given the key role of pathologically enhanced corticostriatal plasticity in LID (Picconi et al. 2003), the striatum seems the most likely site of action.”
BackgroundResultSelf-citationCharacterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit
Roche, K. W., O'Brien, R. J., Mammen, A. L., Bernhardt, J., & Huganir, R. L. (1996) · Neuron · doi:10.1016/s0896-6273(00)80144-0 · Cited by 812
Lee, H.-K., Takamiya, K., Han, J.-S., Man, H., Kim, C.-H., Rumbaugh, G., Yu, S., Ding, L., He, C., Petralia, R. S., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00122-3 · Cited by 802
Gerfen, C. R., & Scott Young, W. (1988) · Brain Research · doi:10.1016/0006-8993(88)91217-6 · Cited by 658
Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase
Banke, T. G., Bowie, D., Lee, H.-K., Huganir, R. L., Schousboe, A., & Traynelis, S. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-01-00089.2000 · Cited by 652
Cited by
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
Self-citationThe Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324
Maladaptive striatal plasticity in l-DOPA-induced dyskinesia
Cenci, M. A., & Konradi, C. (2010) · Progress in Brain Research · doi:10.1016/s0079-6123(10)83011-0 · Cited by 216
“This suggestion is indeed supported by independent behavioural pharmacological studies in both rat and non human primate models of PD (Kobylecki et al., 2010; Konitsiotis et al., 2000).”
ResultSelf-citationMechanisms of Channel Block in Calcium-Permeable AMPA Receptors
Twomey, E. C., Yelshanskaya, M. V., Vassilevski, A. A., & Sobolevsky, A. I. (2018) · Neuron · doi:10.1016/j.neuron.2018.07.027 · Cited by 106
Drug addiction: from bench to bedside
Cheron, J., & Kerchove d’Exaerde, A. D. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01542-0 · Cited by 75
“While these calcium permeable AMPARs are also critical for the pathogenesis of numerous other neurological disorders (including epilepsy [79], fragile X syndrome [80], amyotrophic lateral sclerosis [81], Parkinson’s [82] and Alzheimer’s [83] diseases), developing drugs that specifically target them and not calcium-imp…”
Background
Metadata
- Authors
- Kobylecki, C., Cenci, M. A., Crossman, A. R., & Ravenscroft, P.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2010-06-22
- Volume
- 114
- Issue
- 2
- Pages
- 499-511
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1700865237
- Cited by
- 100
- References
- 8
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Calcium‐permeable AMPA receptors are involved in the induction and expression of l‐DOPA‐induced dyskinesia in Parkinson’s disease. https://app.cochat.ai/papers/10.1111/j.1471-4159.2010.06776.x
- The paper
- Kobylecki, C., Cenci, M. A., Crossman, A. R., & Ravenscroft, P. (2010). Calcium‐permeable AMPA receptors are involved in the induction and expression of l‐DOPA‐induced dyskinesia in Parkinson’s disease. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2010.06776.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.